FBRX — Forte Biosciences Inc
NASDAQ · Healthcare · Biotechnology
$76.97
+$0.02 (+0.03%)
Forte Biosciences Inc (FBRX) is a biotechnology company listed on NASDAQ. It is led by Paul A. Wagner Ph.D., based in 3060 Pegasus Park Drive, Dallas, TX, United States, 75247, with about 22 employees. Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Net income was -$44.6M. FBRX currently screens at market cap $360.2M.
Use this FBRX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the FBRX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the FBRX SEC filings page. Lician reads the product cache first so this HTML stays unique to Forte Biosciences Inc even when a live quote feed is slow.
About Forte Biosciences Inc
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
FBRX Key Statistics
Market Cap
$360.22M
Volume
1.24M
Previous Close
$76.95
Day Range
$76.95 – $76.98
P/B Ratio
8.56
EPS
-$12.17
Revenue
$0.00
Net Income
-$35.48M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
22
FBRX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$35.48M | -$31.48M | -$13.88M | -$21.71M |
| EPS (Diluted) | -$12.17 | -$24.92 | -$0.80 | -$1.55 |
Total Assets
$61.56M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$22.24M
Operating Cash Flow
-$30.75M
Free Cash Flow
$0.00
Forte Biosciences Inc Company Information
- CEO, President & Chairman
- Paul A. Wagner Ph.D.
- Headquarters
- 3060 Pegasus Park Drive, Dallas, TX, United States, 75247
- Website
- www.fortebiorx.com
- Phone
- 310 618 6994
- IPO / Founded
- 2017-04-13
- Sector
- Healthcare
- Industry
- Biotechnology